Insmed (NASDAQ:INSM) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Insmed (NASDAQ:INSM) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $90.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Insmed’s Q1 2025 earnings at ($1.47) EPS, Q2 2025 earnings at ($1.42) EPS, Q3 2025 earnings at ($1.41) EPS and Q4 2025 earnings at ($1.22) EPS.

Several other brokerages have also recently issued reports on INSM. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Stifel Nicolaus raised their price objective on Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. raised their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Finally, Morgan Stanley lifted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average price target of $91.00.

Insmed Stock Performance

INSM stock opened at $81.06 on Friday. Insmed has a 1-year low of $21.92 and a 1-year high of $84.91. The business has a 50-day moving average price of $74.29 and a 200 day moving average price of $73.61. The company has a market capitalization of $14.50 billion, a P/E ratio of -14.50 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. As a group, equities research analysts forecast that Insmed will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In other Insmed news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the completion of the transaction, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 532,207 shares of company stock worth $41,400,465. Company insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in INSM. Elequin Capital LP purchased a new stake in Insmed in the fourth quarter valued at $28,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC boosted its stake in shares of Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares during the last quarter. Spire Wealth Management acquired a new stake in Insmed during the fourth quarter worth about $47,000. Finally, Smartleaf Asset Management LLC raised its position in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 411 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.